Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Bermejo, I. orcid.org/0000-0001-9105-8088, Stevenson, M., Archer, R. et al. (5 more authors) (2017) Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 35 (11). pp. 1141-1151. ISSN 1170-7690

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2017 Springer Verlag. This is an author produced version of a paper subsequently published in PharmacoEconomics. The final publication is available at Springer via http://dx.doi.org/10.1007/s40273-017-0521-5. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Accepted: 18 May 2017
  • Published (online): 26 May 2017
  • Published: November 2017
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Depositing User: Symplectic Sheffield
Date Deposited: 30 May 2017 10:26
Last Modified: 10 Feb 2020 11:24
Published Version: https://doi.org/10.1007/s40273-017-0521-5
Status: Published
Publisher: Springer Verlag
Refereed: Yes
Identification Number: https://doi.org/10.1007/s40273-017-0521-5
Related URLs:

Share / Export

Statistics